The CHST3 gene plays a pivotal role in the development and maintenance of the skeletal system. Mutations in this gene can lead to a rare genetic disorder known as Spondyloepiphyseal Dysplasia with Congenital Joint Dislocations (SEDC-JD), characterized by skeletal abnormalities, including short stature, spinal issues, and joint dislocations present from birth. To diagnose this condition, genetic testing of the CHST3 gene is crucial.
DNA Labs UAE offers a specialized genetic test to identify mutations in the CHST3 gene, aiding in the diagnosis of Spondyloepiphyseal Dysplasia with Congenital Joint Dislocations. This test is essential for individuals showing symptoms of the disorder or those with a family history of skeletal dysplasias. Early diagnosis can facilitate appropriate medical interventions, management strategies, and genetic counseling for affected families.
The cost of the CHST3 Gene Spondyloepiphyseal Dysplasia with Congenital Joint Dislocations Genetic Test at DNA Labs UAE is 4400 AED. This test is conducted using advanced genetic sequencing technologies to ensure accurate and reliable results, providing crucial information for the management and treatment of this rare condition.
The DDR2 Gene Spondylometaepiphyseal Dysplasia Short Limb-Hand Type Genetic Test is a specialized diagnostic procedure offered by DNA Labs UAE. Priced at 4400 AED, this test specifically targets the DDR2 gene, which has been associated with Spondylometaepiphyseal Dysplasia, Short Limb-Hand Type (SMED-SL), a rare genetic disorder. SMED-SL is characterized by short stature, short limbs and hands, and other skeletal abnormalities. The condition is inherited in an autosomal recessive manner, meaning that both copies of the gene in each cell have mutations.
This genetic test is crucial for accurate diagnosis, enabling early intervention and management strategies for affected individuals. It involves collecting a DNA sample, typically through a blood draw or cheek swab, and analyzing the DDR2 gene for specific mutations known to cause the disorder. By identifying the genetic cause, families can also receive information about the risk of the disorder in future pregnancies. DNA Labs UAE provides this service with state-of-the-art technology and expert analysis, ensuring reliable results for patients and their families.
The KRT17 Gene Steatocystoma Multiplex Genetic Test is a specialized diagnostic tool offered by DNA Labs UAE, designed to identify mutations in the KRT17 gene, which are known to cause Steatocystoma Multiplex. This condition is characterized by the development of multiple, non-cancerous cysts primarily affecting the skin's sebaceous glands. The test plays a crucial role in confirming the diagnosis, allowing for appropriate management and counseling of affected individuals. Priced at 4400 AED, this genetic test involves collecting a DNA sample, typically through a blood draw or cheek swab, and analyzing it for specific mutations in the KRT17 gene. The results can provide valuable information regarding the genetic basis of the condition, potential implications for family members, and contribute to a better understanding of the disorder's pathogenesis and variability in its clinical presentation.
The FBN1 Gene Stiff Skin Syndrome Genetic Test is a specialized diagnostic tool used to identify mutations in the FBN1 gene, which are associated with Stiff Skin Syndrome (SSS). This condition is a rare genetic disorder characterized by hard, thick skin that can limit mobility and cause discomfort. The test is crucial for early diagnosis and management of the condition, enabling healthcare professionals to tailor treatment plans to the specific needs of the patient.
Conducted at DNA Labs UAE, a leading facility in genetic testing, the test offers a comprehensive analysis of the FBN1 gene. With state-of-the-art technology and a team of expert geneticists, DNA Labs UAE ensures accurate and reliable results. The cost of the test is 4400 AED, an investment in obtaining crucial genetic information that can significantly impact the patient's quality of life and management of Stiff Skin Syndrome.
The DNASE1 Gene Systemic Lupus Erythematosus (SLE) Genetic Test is a specialized diagnostic tool offered by DNA Labs UAE, designed to identify mutations in the DNASE1 gene that are associated with an increased risk of developing Systemic Lupus Erythematosus. SLE is a complex autoimmune disease characterized by the immune system attacking its own tissues, leading to inflammation and damage to various body systems, including the skin, joints, kidneys, and brain.
The DNASE1 gene plays a critical role in the body's immune response by producing an enzyme that degrades DNA from dying cells, preventing the immune system from mounting a response against self-antigens. Mutations in this gene can impair this process, leading to the accumulation of DNA from dead cells, potentially triggering an autoimmune response.
The test involves collecting a DNA sample, typically through a blood draw or cheek swab, which is then analyzed in the laboratory to detect any genetic variations in the DNASE1 gene that are linked to SLE. This genetic test is particularly valuable for individuals with a family history of SLE or those exhibiting symptoms of the disease, as it can provide crucial information for diagnosis, risk assessment, and management of the condition.
The cost of the DNASE1 Gene Systemic Lupus Erythematosus Genetic Test at DNA Labs UAE is 4400 AED. This investment can be an important step in understanding an individual's genetic predisposition to SLE, enabling proactive health management strategies and personalized medical care.
The LMNA Gene Restrictive Dermopathy Lethal Genetic Test is a specialized diagnostic examination conducted at DNA Labs UAE, designed to detect mutations in the LMNA gene, which are known to cause Restrictive Dermopathy (RD), a rare and lethal genetic disorder. RD is characterized by tight, rigid skin that leads to severe developmental issues, including skeletal abnormalities, and typically results in death shortly after birth. This test, priced at 4400 AED, is crucial for prospective parents with a family history of RD or those identified as carriers of LMNA gene mutations. By analyzing a small sample of blood or tissue, the test provides vital information on the genetic health of the fetus, enabling early diagnosis and the opportunity for families to make informed decisions about their pregnancy. DNA Labs UAE employs advanced genetic testing technologies to ensure accurate and reliable results, offering essential support to families facing the challenges of genetic disorders.
ZMPSTE24 Gene Restrictive Dermopathy Lethal Genetic Test is a specialized diagnostic assessment offered by DNA Labs UAE, designed to identify mutations in the ZMPSTE24 gene, which are linked to Restrictive Dermopathy (RD), a rare and lethal genetic disorder. RD is characterized by tight, rigid skin that leads to severe developmental issues within the body and, most often, results in fatality either in utero or shortly after birth. The ZMPSTE24 gene plays a crucial role in the maturation of lamin A, a protein vital for the structural integrity and function of the nuclear envelope in cells. Mutations in this gene disrupt the production or function of mature lamin A, leading to the manifestations of RD.
The test is particularly valuable for prospective parents with a family history of RD or related symptoms, as well as for medical professionals managing pregnancies with suspected cases of RD. By employing advanced genetic sequencing techniques, DNA Labs UAE ensures a comprehensive analysis of the ZMPSTE24 gene, aiming to provide accurate and reliable results.
The cost of the ZMPSTE24 Gene Restrictive Dermopathy Lethal Genetic Test at DNA Labs UAE is set at 4400 AED. This price reflects the intricate processes involved in the genetic analysis and the expertise required to interpret the results accurately. Patients considering this test are advised to consult with a genetic counselor or a healthcare professional to understand the implications of the results and to discuss the appropriate next steps based on the outcome of the test.
The AK2 Gene Reticular Dysgenesis Genetic Test is a specialized diagnostic procedure designed to identify mutations in the AK2 gene, which are associated with a rare and severe form of immunodeficiency known as reticular dysgenesis. This condition is characterized by a profound deficiency of granulocytes (a type of white blood cell important for fighting bacterial infections), lymphocytes (essential for immune response), and sensorineural deafness, leading to severe infections from a very early age.
The test is crucial for early diagnosis and management of the condition, allowing for appropriate treatment strategies to be implemented, which may include bone marrow transplantation among other interventions. Early detection through this genetic testing can significantly improve the prognosis by preventing severe infections and other complications associated with the disorder.
The test is conducted at DNA Labs UAE, a leading facility in genetic diagnostics that offers a comprehensive range of genetic testing services. The cost of the AK2 Gene Reticular Dysgenesis Genetic Test is 4400 AED, reflecting the specialized nature of the test and the sophisticated technology used to identify the genetic mutations accurately. This investment in the test can be invaluable for affected families in guiding treatment decisions and providing a clearer understanding of the condition's implications.
The ADAM10 gene plays a crucial role in various cellular processes, including cell proliferation, differentiation, and migration. Mutations in this gene have been associated with Reticulate Acropigmentation of Kitamura (RAPK), a rare genetic skin disorder. This condition is characterized by pigmented macules on the hands and feet, which often expand and merge to form a reticulate pattern. The disorder may also feature skin pits and lesions that resemble scars.
To diagnose this condition accurately, genetic testing for mutations in the ADAM10 gene is crucial. DNA Labs UAE offers a specific genetic test for Reticulate Acropigmentation of Kitamura, aimed at identifying mutations in the ADAM10 gene. This test is a valuable tool for dermatologists and geneticists in diagnosing RAPK, facilitating appropriate management and counseling for affected individuals and their families.
The cost of the ADAM10 Gene Reticulate Acropigmentation of Kitamura Genetic Test at DNA Labs UAE is 4400 AED. This comprehensive test is conducted with the highest standards of accuracy and reliability, ensuring that patients receive precise information about their genetic condition. DNA Labs UAE utilizes advanced genetic sequencing technologies to analyze the ADAM10 gene, providing insights into the specific mutations responsible for RAPK in a patient. This test is an important step towards personalized medicine for individuals with this rare genetic disorder, offering a clear diagnosis that can guide treatment and management decisions.
The AFF3 gene, associated with rheumatoid arthritis susceptibility, is a focus of genetic testing aimed at identifying individuals at increased risk for developing this chronic inflammatory disorder. Rheumatoid arthritis (RA) is an autoimmune condition characterized by pain, swelling, and stiffness in the joints, and understanding genetic predispositions can be crucial in its early detection and management.
DNA Labs UAE offers a comprehensive genetic test targeting the AFF3 gene to evaluate an individual's susceptibility to rheumatoid arthritis. This test is particularly valuable for those with a family history of RA or who exhibit early symptoms of the disease. By analyzing specific genetic markers within the AFF3 gene, the test can provide insights into a person's risk level, enabling proactive health management strategies.
The cost of the AFF3 gene rheumatoid arthritis susceptibility genetic test at DNA Labs UAE is 4400 AED. This investment covers the collection of a DNA sample, usually through a simple and non-invasive saliva or blood test, the genetic analysis of the AFF3 gene, and a comprehensive report detailing the findings. The results can offer invaluable information for both individuals and healthcare providers, facilitating personalized treatment plans and potentially reducing the impact of rheumatoid arthritis on the patient's life.
